1240321-53-2
Chemical Structure
Valecobulin hydrochloride
Synonym(s): CKD-516 hydrochloride
- CAS. Nr.: 1240321-53-2
- Formula:C26H29ClN6O5S
- Molecular Weight:573.06
IUPAC Name: (S)-N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide hydrochloride
InChIKey: FIAUXCMEQTWLQZ-FTBISJDPSA-N
SMILES: CC(C)[C@H](N)C(NC1=NC(C2=CC=C(C(C3=CC(OC)=C(OC)C(OC)=C3)=O)C(N4N=CN=C4)=C2)=CS1)=O.Cl
Biological Activity: Valecobulin hydrochloride (CKD-516 hydrochloride) is a valine proagent of S516 (HY-130233) and a vascular disrupting agent (VDA). Valecobulin hydrochloride is a potent β-tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors[1][2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Valecobulin hydrochloride | 98.46% | Valecobulin hydrochloride (CKD-516 hydrochloride) is a valine proagent of S516 (HY-130233) and a vascular disrupting agent (VDA). Valecobulin hydrochloride is a potent β-tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.99
HY-13598Valecobulin -
Similarity Score 0.79
HY-130233S516 -
Similarity Score 0.50
HY-175713Tubulin/CDC5L-IN-1 -
Similarity Score 0.49
HY-Q49697Sirtuin modulator 3 -
Similarity Score 0.49
HY-146357Anticancer agent 48 -
Similarity Score 0.49
HY-103368REact (Standard) -
Similarity Score 0.49
HY-146358Anticancer agent 49 -
Similarity Score 0.49
HY-19616ML278 -
Similarity Score 0.49
HY-185146O-GlcNAcase-IN-5 -
Explore the MedChemAI to find more analogs
References
- [1]. Lee J, et al. Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors. J Med Chem. 2010 Sep 9;53(17):6337-54. [Content Brief]
- [2]. Joo I, et al. Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors. Radiology. 2014 Aug;272(2):417-26. [Content Brief]
